Drug Profile
Levonorgestrel - AbbVie
Alternative Names: AVIBELA; Levonorgestrel intrauterine - AbbVie; Levosert; LILETTA; LNG20Latest Information Update: 12 Jul 2023
Price :
$50
*
At a glance
- Originator Mithra Pharmaceuticals
- Developer AbbVie; Medicines360; Population Services International
- Class Hormonal contraceptives; Hormonal replacements; Norpregnanes; Progesterone congeners; Small molecules
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Menorrhagia; Pregnancy
Most Recent Events
- 10 Jul 2023 Registered for Menorrhagia in USA (Intrauterine)
- 10 Jul 2023 The US FDA approves sNDA for extension of use of levonorgestrel for up to five years for Menorrhagia in USA (Intrauterine)
- 14 Nov 2022 The US FDA approves sNDA for extension of use of levonorgestrel intrauterine for up to eight years Contraception in USA